SciELO - Scientific Electronic Library Online

vol.37 issue4Characteristics of oncological clinical trials submitted to the Instituto Nacional de Salud del Peru, 1995-2019Sleep disorders as a result of the COVID-19 pandemic author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista Peruana de Medicina Experimental y Salud Publica

Print version ISSN 1726-4634


GALVAN, César A. et al. Transfusion of convalescent plasma from patients with COVID -19. Rev. perú. med. exp. salud publica [online]. 2020, vol.37, n.4, pp.746-754.  Epub Nov 09, 2020. ISSN 1726-4634.

There is currently no vaccine available and no specific medication against Coronavirus 2019 disease (COVID-19). The treatment is mainly based on support measures. In this context, several potentially useful therapies have been approved for use in clinical trials, such as convalescent plasma transfusion (CPT). PubMed was searched for studies on convalescent plasma and COVID-19, SARS or MERS. Studies on clinical efficacy in diseases caused by other coronaviruses (SARS-CoV and MERS-CoV) showed clinical improvement, increase of neutralizing antibodies, decreased mortality and absence of adverse events during and after treatment. We found 13 studies on this type of treatment used in patients with severe and critical COVID-19. Despite limitations regarding methodology, number of patients and the protocols for the analysis of donors’ convalescent plasma, patients who received CPT showed clinical improvement, improvement of ventilatory patterns, resolution of lung injuries, decreased mortality, improvement of laboratory parameters, increase of neutralizing antibodies, decreased viral load and low frequency of adverse events.

Keywords : COVID-19; Plasma; MERS Virus; SARS Virus.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )